Susquehanna International Group
ASND icon

Susquehanna International Group’s Ascendis Pharma A/S ASND Stock Holding History

Susquehanna International Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.9M Buy
305,500
+108,700
+55% +$24.4M 0.01% 1043
2025
Q4 		$42M Buy
196,800
+79,900
+68% +$16.5M ﹤0.01% 1519
2025
Q3 		$23.2M Buy
116,900
+71,200
+156% +$13.3M ﹤0.01% 2043
2025
Q2 		$7.89M Sell
45,700
-17,400
-28% -$2.83M ﹤0.01% 3188
2025
Q1 		$9.83M Buy
63,100
+33,700
+115% +$4.81M ﹤0.01% 2560
2024
Q4 		$4.05M Sell
29,400
-91,900
-76% -$12.1M ﹤0.01% 3926
2024
Q3 		$18.1M Buy
121,300
+41,800
+53% +$5.64M ﹤0.01% 1932
2024
Q2 		$10.8M Buy
79,500
+12,400
+18% +$1.69M ﹤0.01% 2381
2024
Q1 		$10.1M Sell
67,100
-11,400
-15% -$1.63M ﹤0.01% 2582
2023
Q4 		$9.89M Buy
78,500
+44,000
+128% +$4.39M ﹤0.01% 2659
2023
Q3 		$3.23M Sell
34,500
-23,000
-40% -$2.15M ﹤0.01% 4254
2023
Q2 		$5.13M Sell
57,500
-222,100
-79% -$19.3M ﹤0.01% 3487
2023
Q1 		$30M Buy
279,600
+125,400
+81% +$14.3M 0.01% 1319
2022
Q4 		$18.8M Buy
154,200
+125,200
+432% +$14.5M ﹤0.01% 1584
2022
Q3 		$3M Sell
29,000
-66,200
-70% -$6.28M ﹤0.01% 4097
2022
Q2 		$8.85M Buy
95,200
+13,600
+17% +$1.28M ﹤0.01% 2374
2022
Q1 		$9.58M Buy
81,600
+72,500
+797% +$8.4M ﹤0.01% 2606
2021
Q4 		$1.22M Sell
9,100
-18,900
-68% -$2.81M ﹤0.01% 6738
2021
Q3 		$4.46M Sell
28,000
-8,700
-24% -$1.19M ﹤0.01% 4168
2021
Q2 		$4.83M Buy
36,700
+10,900
+42% +$1.45M ﹤0.01% 4099
2021
Q1 		$3.33M Buy
25,800
+18,400
+249% +$2.8M ﹤0.01% 4739
2020
Q4 		$1.23M Sell
7,400
-22,000
-75% -$3.64M ﹤0.01% 6206
2020
Q3 		$4.54M Sell
29,400
-86,600
-75% -$12.4M ﹤0.01% 3185
2020
Q2 		$17.2M Buy
116,000
+34,200
+42% +$4.7M ﹤0.01% 1569
2020
Q1 		$9.21M Sell
81,800
-94,200
-54% -$12.2M ﹤0.01% 1823
2019
Q4 		$24.5M Sell
176,000
-218,900
-55% -$24.3M 0.01% 1247
2019
Q3 		$38M Sell
394,900
-47,100
-11% -$5.25M 0.01% 902
2019
Q2 		$50.9M Sell
442,000
-372,600
-46% -$44.6M 0.02% 678
2019
Q1 		$95.9M Buy
814,600
+386,400
+90% +$33.8M 0.04% 382
2018
Q4 		$26.8M Buy
428,200
+393,700
+1,141% +$24.7M 0.01% 905
2018
Q3 		$2.44M Buy
34,500
+3,800
+12% +$262K ﹤0.01% 3682
2018
Q2 		$2.04M Buy
+30,700
New +$2.02M ﹤0.01% 3983

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's ASND Position: Q1 2026 in Review

Susquehanna International Group reduced its Ascendis Pharma A/S (ASND) stake by 94% in Q1 2026, selling an estimated $99.3M and leaving 28,062 shares worth $6.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

Susquehanna International Group first reported a position in ASND in Q2 2018 and has held it in 24 quarters since. The position peaked at $100M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Susquehanna International Group held 28,062 shares of Ascendis Pharma A/S worth $6.42M as of Q1 2026.
  • Susquehanna International Group sold 442,889 Ascendis Pharma A/S shares in Q1 2026, an estimated $99.3M.
  • Ascendis Pharma A/S made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3824 holding.
  • Susquehanna International Group first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 24 quarters since.
  • Susquehanna International Group's Ascendis Pharma A/S position peaked at $100M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.